A pioneering cannabis-based medicine for multiple sclerosis from GW Pharmaceuticals has been filed for approval in Europe.
After numerous delays, the submission to regulators in the UK and Spain is a landmark for the British drug maker, which yesterday posted a maiden first-half net profit of £4 million (R52m).
Clinical trials have shown GW's drug Sativex, which is sprayed under the tongue, reduces spasticity in multiple sclerosis patients. - Reuters